Literature DB >> 21801580

COPD heterogeneity: what this will mean in practice.

Stephen I Rennard1.   

Abstract

COPD is a complex collection of conditions. All share the feature of limited expiratory air flow. It is a "disease" in the same sense as is "chronic renal failure." Like most other chronic organ failure "diseases," COPD has disparate causes, and patients are heterogeneous in their prognosis and response to treatment. Unlike many other diseases, the heterogeneity of COPD is just beginning to be described. A number of large trials funded by the National Institutes of Health and industry promise to refine the classification of COPD. Based on accurate diagnosis of COPD subtypes, novel treatments can be more effectively developed and implemented. The clinical implications of improved understanding of COPD heterogeneity will be better care and outcomes for COPD patients, which will depend on increased diagnostic accuracy and selective administration of treatments.

Entities:  

Mesh:

Year:  2011        PMID: 21801580     DOI: 10.4187/respcare.01419

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  5 in total

1.  IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13.

Authors:  Min-Jong Kang; Je-Min Choi; Bo Hye Kim; Chang-Min Lee; Won-Kyung Cho; Gina Choe; Do-Hyun Kim; Chun Geun Lee; Jack A Elias
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

2.  Role of Chitinase 3-Like-1 in Interleukin-18-Induced Pulmonary Type 1, Type 2, and Type 17 Inflammation; Alveolar Destruction; and Airway Fibrosis in the Murine Lung.

Authors:  Min-Jong Kang; Chang Min Yoon; Milang Nam; Do-Hyun Kim; Je-Min Choi; Chun Geun Lee; Jack A Elias
Journal:  Am J Respir Cell Mol Biol       Date:  2015-12       Impact factor: 6.914

3.  Gait mechanics in patients with chronic obstructive pulmonary disease.

Authors:  Jennifer M Yentes; Kendra K Schmid; Daniel Blanke; Debra J Romberger; Stephen I Rennard; Nicholas Stergiou
Journal:  Respir Res       Date:  2015-02-28

4.  Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.

Authors:  Anthony D'Urzo; Giovanni Bader; Steven Shen; Pankaj Goyal; Pablo Altman
Journal:  NPJ Prim Care Respir Med       Date:  2018-05-24       Impact factor: 2.871

5.  Environmental and Genetic Factors in the Pathogenesis of COPD in the Road-Working Population.

Authors:  Yumin Zhou; Man Wang; Weiyan Yang; Jianjun Li; Jialin Li; Yueying Hu; Wei Wang; Chunli Che; Hong Qi
Journal:  Dis Markers       Date:  2021-04-29       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.